Please login to the form below

Not currently logged in
Email:
Password:

NOACs

This page shows the latest NOACs news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs

Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting

Latest news

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    Outside oncology, BMS’ top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    The NOAC has 'very little' chance of showing overall benefit, says data monitoring committee. ... Bayer and Johnson &Johnson have abandoned a 7, 000-patient trial pitting their novel oral anticoagulant (NOAC) Xarelto against aspirin for ischaemic stroke

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    Overall J&J's group sales rose almost 2% to $18.9bn in the second quarter, with novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) rising 8% to $642m in the quarter and

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    The new trial results now show - for the first time - that a NOAC is even more effective. ... Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as

  • Portola rejection hands advantage to Boehringer's Pradaxa Portola rejection hands advantage to Boehringer's Pradaxa

    In October 2015 the FDA granted accelerated approval to Boehringer's Praxbind (idarucizumab) reversal agent for Pradaxa, which seems to have had an impact on sales of the NOAC. ... The thrombin inhibitor is still lagging well behind the market leader in

More from news
Approximately 11 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • NOAC Education: Empowering Stroke Prevention

    The use of oral anticoagulants in patients with atrial fibrillation. NOAC reversal agents. ... PCM Scientific is always open to additional sources of funding support to expand the educational offerings of the NOAC education site.

  • Cogora

    PCM Scientific, Cogora’s CME division, developed NOAC Education as an independent educational initiative with a single, central goal: to support clinicians in providing optimal anticoagulation care for patients at risk

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics